NovelMed’s Ruxoprubart, a novel complement-targeting immunotherapy, has shown positive interim results in a Phase II trial for Paroxysmal Nocturnal Hemoglobinuria (PNH). The drug met all primary efficacy endpoints, demonstrating safety and tolerability while improving key disease markers. This success follows a safe Phase I trial in healthy volunteers.
This development is potentially transformative for PNH patients, who currently face limited treatment options. Current standard-of-care treatments can leave a significant number of patients anemic and reliant on blood transfusions. Ruxoprubart’s success in achieving transfusion avoidance, increasing hemoglobin levels, and reducing LDH suggests a potential for improved quality of life and disease management compared to existing therapies. The once-weekly subcutaneous administration also offers a practical advantage over current treatments requiring more frequent dosing.
Ruxoprubart operates by selectively inhibiting the Alternative Pathway of the complement system without affecting the Classical Pathway. This targeted approach differentiates it from other complement blockers that carry black box warnings due to broad immunosuppression. In the Phase II trial, ten of twelve PNH subjects completed the study, demonstrating improvements in key metrics such as transfusion avoidance, hemoglobin levels, LDH reduction, and preservation of PNH cells. Notably, the drug also facilitated normal pathogenic clearance in all treated subjects. Further, the FDA has granted Orphan Drug Designation to Ruxoprubart for PNH and a Breakthrough Therapy Designation application is forthcoming.
The positive interim results pave the way for a Phase III trial and potential regulatory approval. If successful, Ruxoprubart could become a first-in-class immunotherapy for PNH offering a safer and more effective treatment option. Its unique mechanism of action also holds promise for its application in other complement-mediated diseases, potentially expanding NovelMed’s therapeutic portfolio into areas such as renal, dermatological, and ocular diseases.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
